Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) dropped 9.6% on Friday after Canaccord Genuity Group lowered their price target on the stock from $57.00 to $56.00. Canaccord Genuity Group currently has a buy rating on the stock. Tandem Diabetes Care traded as low as $30.13 and last traded at $30.13. Approximately 2,395,340 shares were traded during trading, an increase of 50% from the average daily volume of 1,600,117 shares. The stock had previously closed at $33.32.
Several other research analysts also recently commented on TNDM. Barclays raised their target price on Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Piper Sandler restated an “overweight” rating and issued a $55.00 target price (up previously from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Morgan Stanley restated an “equal weight” rating and issued a $45.00 target price on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Robert W. Baird cut their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Canaccord Genuity Group initiated coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 target price for the company. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and a consensus price target of $54.25.
Check Out Our Latest Analysis on TNDM
Hedge Funds Weigh In On Tandem Diabetes Care
Tandem Diabetes Care Trading Down 8.2 %
The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. The stock has a fifty day moving average of $38.73 and a two-hundred day moving average of $41.81. The company has a market capitalization of $2.00 billion, a PE ratio of -15.85 and a beta of 1.36.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
- Five stocks we like better than Tandem Diabetes Care
- How Technical Indicators Can Help You Find Oversold Stocks
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- The 3 Best Fintech Stocks to Buy Now
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Buy P&G Now, Before It Sets A New All-Time High
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.